AlphAIAlphAI — Financial news for AI agents
investing.com$XRAY

Dentsply earnings missed by $0.02, revenue fell short of estimates

Dentsply (XRAY) reported Q3 EPS of $0.29, missing estimates by $0.02, with revenue at $836M, below the $862.76M consensus. The stock is down 16.75% over 3 months and 8.44% over 12 months. InvestingPro rates its financial health as 'good performance'.

Original reporting
investing.com
Published Nov 5, 2026, 11:39 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 11:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$XRAY
Bearish
high confidence
Mentioned
$XRAY
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$XRAYBearishMed
01

Why it matters

The earnings shortfall may trigger short-term volatility, but the company's long-term fundamentals remain intact.

02

Market read

Earnings miss creates a near-term trading opportunity for XRAY, with potential downside pressure.

03

What to watch

Potential cost reductions or upcoming product launches not reflected in the quarter could support longer-term upside.

Relevance 8/10Novelty 8/10Timing: after-hours reaction

Background

Dentsply is a leading dental products manufacturer; its earnings are closely watched by healthcare investors.

Company-level read

Ticker impact

$XRAYBearishHigh confidence
Context

Dentsply (XRAY) reported Q3 EPS of $0.29, missing estimates by $0.02 and revenue of $836M, below the $862.76M consensus.

Expected impact

likely downside as market prices in the earnings shortfall

Evidence & confidence

The miss on both EPS and revenue is a fresh disclosure and typically triggers a sell-off in the immediate session.

Market effects

Sector

Dental equipment sector may see modest pressure as peers' valuations adjust to earnings trends.

Regional

U.S. market participants focused on healthcare equipment earnings.

Global

Limited to investors tracking U.S. dental and medical device stocks.

Counterpoint

What could challenge this read

The miss is marginal; the stock may be oversold and could rebound on broader market strength.

Key entities

  • Company
    Dentsply

    Dental products manufacturer reporting Q3 results.

Read at source← All news

StoryDentsply Sirona reports Q3 2026 miss and cuts full‑year sales and EPS outlook

Also covered by

4 outlets

Related articles

HighAI 8/10

DENTSPLY (XRAY) Q3 2026 Earnings Call Transcript

DENTSPLY SIRONA (XRAY) reported Q3 2026 revenue of $836M, down 7.6%, and adjusted EPS of $0.29. The company lowered its full-year guidance to $3.5B in sales and $1.20-$1.30 in adjusted EPS, citing business pressures and investment in growth initiatives. Wellspect Healthcare saw record sales growth, while other segments faced challenges.

finance.yahoo.com
$XRAYMedAI 8/10

Dentsply Sirona (XRAY) stock trades down, here is why

Dentsply Sirona (XRAY) shares fell 7% after reporting a Q3 2026 GAAP loss of $0.01 per share and lowering its full-year outlook. Net sales were $836M, missing estimates. The company now expects 2026 net sales of $3.5B and adjusted EPS of $1.20-$1.30. Shares are down 17.4% YTD and 36.6% below their 52-week high.

financialcontent.com
$XRAYMed

BofA cuts Dentsply Sirona stock price target on guidance reset

BofA Securities reduced its price target for Dentsply Sirona (XRAY) to $14 from $17, citing disappointing Q3 results and a revised 2026 EPS guidance of $1.10. The stock trades near its 52-week low at $8.14. BofA noted positive developments in some segments but expects growth stabilization over time. XRAY's Q3 earnings and revenue missed estimates, leading to a stock price drop.

investing.com
HighAI 8/10

Why is Dentsply Sirona stock plunging today?

Dentsply Sirona (XRAY) shares fell 13% in pre-market trading after Q3 2026 results missed estimates, with revenue at $836M (-7.5% YoY) and EPS at $0.29. The company lowered full-year guidance, and analysts cut price targets, citing segment weakness and a challenging growth outlook.

investing.com
Med

Dentsply Sirona 3Q 2026: Revenue $836M, EPS ($0.01) — 10-Q Summary

Dentsply Sirona (XRAY) reported 3Q 2026 revenue of $836M, down 7.5% YoY, and a net loss of $2M, improved from a $427M loss last year. Sales declines were driven by lower implant volumes and reduced sales in certain regions, partially offset by higher Wellspect volumes. Gross margin increased to 52.9%. The company expects $60M–$65M in total restructuring charges with $100M in annualized savings.

tradingview.com
$XRAYMed

Dentsply: Q3 Earnings Snapshot

Dentsply International (XRAY) reported a Q3 loss of $2 million, or 1 cent per share, with adjusted earnings of 29 cents per share, missing estimates. Revenue was $836 million, also below expectations. The company forecasted full-year earnings of $1.20-$1.30 per share and $3.5 billion in revenue.

finance.yahoo.com